UPDATED: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report

John Carroll

Four days after Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase (Btk) inhibitor acalabrutinib, has popped up as a potential buyer. Dow Jones reported Friday afternoon that the pharma giant is well down the road in talks to buy Acerta for more than $ 5 billion, potentially landing another cancer drug for its growing oncology pipeline.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS